StockNews.AI
ZYXI
StockNews.AI
119 days

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zynex, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZYXI

1. Class action lawsuit filed against Zynex for alleged securities fraud. 2. Prior financial reports indicated revenue shortfalls due to delayed payments. 3. Tricare has suspended payments, representing 20-25% of Zynex's annual revenue. 4. Stock price previously fell 51.3% after revealing financial issues. 5. Pomerantz LLP is leading the class action representing affected investors.

4m saved
Insight
Article

FAQ

Why Very Bearish?

Zynex has faced significant stock declines due to fraud allegations and payment issues. Historical context indicates that similar lawsuits lead to prolonged stock price depressions.

How important is it?

The article highlights substantial legal challenges Zynex faces, directly impacting investor sentiment. The ongoing lawsuit and financial issues point to severe risks for current and prospective investors.

Why Long Term?

The ongoing nature of the class action and scrutiny can affect investor confidence long-term. Past instances show protracted time frames for companies to recover from legal troubles.

Related Companies

NEW YORK, April 22, 2025 /PRNewswire/ --

Pomerantz LLP announces that a class action lawsuit has been filed against Zynex, Inc. ("Zynex" or the "Company") (NASDAQ: ZYXI). Such investors are advised to contact Danielle Peyton at email@example.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether Zynex and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until May 19, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Zynex securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.

Click here for information about joining the class action

On June 4, 2024, medical journal STAT published a report on Zynex entitled "How a device maker inundated pain patients with unwanted batteries and surprise bills." The report claimed Zynex engaged in an "oversupplying scheme" by sending inordinate amounts of monthly supplies like electrode pads and batteries in order to "bill insurers for thousands of dollars more than it otherwise could." The report further revealed that, as a result of this practice, insurers were "kicking the company out of network."

On this news, Zynex's stock price fell $0.50 per share, or 5%, to close at $9.35 per share on June 4, 2024.

Then, on March 11, 2025, Zynex reported its fourth quarter and full year 2024 financial results, revealing a revenue "shortfall" in the quarter "due to slower than normal payments from certain payers." Zynex also revealed that Tricare, the healthcare program for uniformed service members that "currently represents approximately 20-25% of [the Company's] annual revenue," "has temporarily suspended payments as they review prior claims."

On this news, Zynex's stock price fell $3.59 per share, or 51.3%, to close at $3.41 per share on March 12, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT: Danielle Peyton

Pomerantz LLP

email@example.com

646-581-9980 ext. 7980

SOURCE Pomerantz LLP

Related News